FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089969445> ?p ?o ?g. }

• W3089969445 endingPage "1677" @default.
• W3089969445 startingPage "1672" @default.
• W3089969445 abstract "Background Invasive vulvar Paget’s disease with over-expression of the human epidermal growth factor receptor 2 (HER2) protein is potentially suitable for targeted therapy, especially in a metastatic setting where no effective treatments are available. Methods Four consecutive patients with HER2 positive advanced vulvar Paget’s disease, treated with weekly trastuzumab (loading dose 4 mg/kg, then 2 mg/kg) and paclitaxel (80 mg/m 2 ) followed by 3-weekly trastuzumab maintenance (6 mg/kg), are reported. Results Median age and follow-up of patients were 62.5 years (45–74) and 16 months (6-54), respectively. Complete or partial responses were observed in all patients. Median time to response was 3 months (range 2–4), while median duration of response was 10 months (range 2–34). Case 1 presented with pulmonary and lymph nodes involvement. She experienced a radiological complete response after 24 treatment administrations, and a progression-free survival of 36 months. At disease progression, treatment re-challenge achieved partial response. She is currently receiving treatment with trastuzumab–emtansine. Case 2 was a 74-year-old woman who developed pulmonary metastasis after first-line cisplatin treatment. She had a partial response and a progression-free survival of 10 months. Case 3 had inguinal and para-aortic lymphadenopathy in complete response after 18 treatment administrations. She developed brain metastasis while receiving trastuzumab maintenance. Case 4 was treated for locally advanced disease and experienced a subjective benefit with relief in perineal pain and itching. No unexpected treatment-related side effects were reported. Conclusions Advanced vulvar Paget’s disease is a rare disorder and no standard treatment is available. In the sub-group of HER2 positive disease, weekly paclitaxel–trastuzumab appears to be active and safe, and may be considered a therapeutic option in these patients." @default.
• W3089969445 created "2020-10-08" @default.
• W3089969445 creator A5004811903 @default.
• W3089969445 creator A5007787317 @default.
• W3089969445 creator A5008925729 @default.
• W3089969445 creator A5009976972 @default.
• W3089969445 creator A5013124362 @default.
• W3089969445 creator A5015445323 @default.
• W3089969445 creator A5021100005 @default.
• W3089969445 creator A5023227998 @default.
• W3089969445 creator A5029913023 @default.
• W3089969445 creator A5039767477 @default.
• W3089969445 creator A5043424604 @default.
• W3089969445 creator A5047868780 @default.
• W3089969445 creator A5066280513 @default.
• W3089969445 creator A5066455814 @default.
• W3089969445 creator A5075663363 @default.
• W3089969445 creator A5078791756 @default.
• W3089969445 creator A5083186513 @default.
• W3089969445 creator A5088492598 @default.
• W3089969445 date "2020-09-30" @default.
• W3089969445 modified "2023-09-25" @default.
• W3089969445 title "Human epidermal growth factor receptor-2 (HER2) is a potential therapeutic target in extramammary Paget’s disease of the vulva" @default.
• W3089969445 cites W1668166049 @default.
• W3089969445 cites W2011641228 @default.
• W3089969445 cites W2095575372 @default.
• W3089969445 cites W2096628771 @default.
• W3089969445 cites W2108182027 @default.
• W3089969445 cites W2116613918 @default.
• W3089969445 cites W2146800637 @default.
• W3089969445 cites W2266973524 @default.
• W3089969445 cites W2291627298 @default.
• W3089969445 cites W2417086232 @default.
• W3089969445 cites W2801119026 @default.
• W3089969445 cites W2997401597 @default.
• W3089969445 doi "https://doi.org/10.1136/ijgc-2020-001771" @default.
• W3089969445 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32998859" @default.
• W3089969445 hasPublicationYear "2020" @default.
• W3089969445 type Work @default.
• W3089969445 sameAs 3089969445 @default.
• W3089969445 citedByCount "15" @default.
• W3089969445 countsByYear W30899694452020 @default.
• W3089969445 countsByYear W30899694452021 @default.
• W3089969445 countsByYear W30899694452022 @default.
• W3089969445 countsByYear W30899694452023 @default.
• W3089969445 crossrefType "journal-article" @default.
• W3089969445 hasAuthorship W3089969445A5004811903 @default.
• W3089969445 hasAuthorship W3089969445A5007787317 @default.
• W3089969445 hasAuthorship W3089969445A5008925729 @default.
• W3089969445 hasAuthorship W3089969445A5009976972 @default.
• W3089969445 hasAuthorship W3089969445A5013124362 @default.
• W3089969445 hasAuthorship W3089969445A5015445323 @default.
• W3089969445 hasAuthorship W3089969445A5021100005 @default.
• W3089969445 hasAuthorship W3089969445A5023227998 @default.
• W3089969445 hasAuthorship W3089969445A5029913023 @default.
• W3089969445 hasAuthorship W3089969445A5039767477 @default.
• W3089969445 hasAuthorship W3089969445A5043424604 @default.
• W3089969445 hasAuthorship W3089969445A5047868780 @default.
• W3089969445 hasAuthorship W3089969445A5066280513 @default.
• W3089969445 hasAuthorship W3089969445A5066455814 @default.
• W3089969445 hasAuthorship W3089969445A5075663363 @default.
• W3089969445 hasAuthorship W3089969445A5078791756 @default.
• W3089969445 hasAuthorship W3089969445A5083186513 @default.
• W3089969445 hasAuthorship W3089969445A5088492598 @default.
• W3089969445 hasBestOaLocation W30899694451 @default.
• W3089969445 hasConcept C121608353 @default.
• W3089969445 hasConcept C126322002 @default.
• W3089969445 hasConcept C141071460 @default.
• W3089969445 hasConcept C143998085 @default.
• W3089969445 hasConcept C2776316342 @default.
• W3089969445 hasConcept C2776694085 @default.
• W3089969445 hasConcept C2778822529 @default.
• W3089969445 hasConcept C2779786085 @default.
• W3089969445 hasConcept C530470458 @default.
• W3089969445 hasConcept C71924100 @default.
• W3089969445 hasConcept C90924648 @default.
• W3089969445 hasConceptScore W3089969445C121608353 @default.
• W3089969445 hasConceptScore W3089969445C126322002 @default.
• W3089969445 hasConceptScore W3089969445C141071460 @default.
• W3089969445 hasConceptScore W3089969445C143998085 @default.
• W3089969445 hasConceptScore W3089969445C2776316342 @default.
• W3089969445 hasConceptScore W3089969445C2776694085 @default.
• W3089969445 hasConceptScore W3089969445C2778822529 @default.
• W3089969445 hasConceptScore W3089969445C2779786085 @default.
• W3089969445 hasConceptScore W3089969445C530470458 @default.
• W3089969445 hasConceptScore W3089969445C71924100 @default.
• W3089969445 hasConceptScore W3089969445C90924648 @default.
• W3089969445 hasIssue "11" @default.
• W3089969445 hasLocation W30899694451 @default.
• W3089969445 hasOpenAccess W3089969445 @default.
• W3089969445 hasPrimaryLocation W30899694451 @default.
• W3089969445 hasRelatedWork W1976609613 @default.
• W3089969445 hasRelatedWork W2050439103 @default.
• W3089969445 hasRelatedWork W2057180889 @default.
• W3089969445 hasRelatedWork W2218005127 @default.
• W3089969445 hasRelatedWork W2316766300 @default.
• W3089969445 hasRelatedWork W2394251095 @default.
• W3089969445 hasRelatedWork W2937445726 @default.

• next